Clinical Trial Update: Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tolerability of MK0524A to niacin extended-release in patients with high cholesterol has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• MK0524A
• Niacin Extended-Release (nicotinic acid)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypercholesterolemia, Hyperlipidemia | Phase 3 | Status: COMPLETED